Cerebrolysin in first-degree relatives: cognitive follow-up by ApoE genotype
Observational study · 2020
- What was studied
- 72 first-degree relatives. Forty-six had mild cognitive difficulties and 26 met diagnostic criteria for mild cognitive impairment.
- Main finding
- In 72 treated relatives, the authors reported weaker immediate and follow-up cognitive changes in ApoE4 carriers than in noncarriers.
Reported findings and study design
Findings described in words
Repeated cognitive assessments by baseline severity and ApoE4 genotype.
Population or model 72 first-degree relatives. Forty-six had mild cognitive difficulties and 26 met diagnostic criteria for mild cognitive impairment.
Dose, route and schedule
A four-week intravenous infusion course. Assessments immediately after the course and at one and two months later. The checked abstract does not give the infusion volume.
Protocol source ↗ · Original indexed abstract, subgroup denominators and assessment schedule.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Cognitive outcomes by ApoE4 genotype | The authors report smaller immediate and delayed changes in ApoE4 carriers. | End of course and one- and two-month follow-up |
Source for these results ↗ · Reviewed 2026-11-15
Study limitations and source details
Study limitations
- All participants received treatment. The abstract provides no genotype subgroup sizes or effect estimates. Overlap with other reports from the same center remains unverified.
Related publications may describe some of the same participants or experiments.
Source details
Original indexed abstract, subgroup denominators and assessment schedule.
Sources checked
Citation
N. D. Selezneva, S. I. Gavrilova, I. V. Kolykhalov. Cerebrolysin in first-degree relatives: cognitive follow-up by ApoE genotype Korsakov Journal of Neurology and Psychiatry. 2020;120(10 Suppl 2):31–38.
Study source ↗ · DOI 10.17116/jnevro202012010231 · Bibliography entry · Link to this summary